Actinium
Pharmaceuticals’ Technology |
Components of Alpha Particle Immunotherapy
There are three principle contributing components, which must be coordinated
and managed for successful development and commercialization of alpha
particle immunotherapy technology. These include monoclonal antibodies,
chelators, and radioisotopes.
< larger view >
Monoclonal Antibodies - used to target the alpha particle therapy to the disease site. For a specific cancer, the monoclonal antibody is the site-selective delivery agent, which binds to the tumor cells, either in the bloodstream or in micro-metastases, and delivers the isotope to the tumor cells.
Chelators - the linking molecules used to stably attach the therapeutic to the monoclonal antibody. To utilize the alpha emitting isotopes for cancer treatment, a stable linkage is created between the isotope and the monoclonal antibody.
Radioisotopes - Actinium Pharmaceuticals' technology focuses on the clinical use of two radioisotopes, which have distinct, yet clinically complementary physical characteristics. These isotopes are Bismuth-213 and Actinium-225.
Bismuth-213, with a radioactive decay half-life of 46 minutes, is suitable in applications with relatively rapid delivery kinetics including blood-borne cellular cancers (e.g. lymphomas, myelomas) and micrometastatic disease of certain solid tumor types.
Actinium-225, with a radioactive decay half-life of 10 days, can be used directly in all the Bi-213 targeted tumors and in addition for cancers with slower delivery kinetics compared to those suitable for treatment with Bismuth-213.
< BACK TO TOP >